Fig. 1

Optimization of PCR technique using FLT3/ITD-positive and FLT3/ITD-negative patient. a Using three different DNA concentrations 5, 2.5, and 1.25 ng/μl in FLT3/ITD-positive AML patient. Lane 1 FLT3/ITD detected with 50 ng DNA added, lane 2 FLT3/ITD detected with 25 ng DNA added, lane 3 FLT3/ITD detected with 12.5 ng DNA added, lane 4 no DNA added, and M pUC19 molecular marker. The solid line points to FLT3/ITD bp inserted while the dotted arrow points to the WT FLT3 gene. b Using DNA obtained from different number of cells (2 × 10⁶, 150, 1606 cells in duplicates) on WT FLT3 AML patient based on the number of cells obtained from the first sorted sample (sample no.1 in Table 4). Lanes 1 and 2 (duplicate) DNA obtained from 2 × 10⁶ cells, FLT3 WT detected; lanes 3 and 4 (duplicate) DNA obtained from 150 cells, FLT3 WT detected; lanes 5 and 6 (duplicate) DNA obtained from 1606 cells, FLT3 WT detected; lane 7, no DNA, so the PCR was specific; lanes 8 and 9 are the negative and positive controls and M was pUC19 marker. c DNA fragments (bp) of the molecular marker pUC19